Autres langues Cessatech A/S

Actions

CESSA

DK0061411964

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
6,62 ^DKK	+1,85%		+5,08%	-8,82%

29/02	Cessatech A/S publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Cessatech A/S publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

A short business update	18/04
Minutes from the Annual General Meeting in Cessatech A/S	27/03
Annual General Meeting - 27 March 2024	11/03
Cessatech A/S publishes Annual Report for the fiscal year 2023	29/02
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2	30/01
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024	23/01
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2	22/01
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2	12/01
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD	11/01
Q&A session related topline data Study 0205	04/01
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001	22/12
Third Quarter Report Q3-2023	16/11
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children	25/10/23
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/10/23
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001	21/09/23
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/09/23
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12/09/23
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children	12/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cessatech A/S

Actions

CESSA

DK0061411964

Autres langues

Filtres